Prolaxan10 billion

Prolaxan is a probiotic bacterial strain (a live, non-pathogenic strain of Lactobacillus rhamnosus, designated "GG") used for the following indications:

Established / guideline-supported uses

• Prevention and shortening of the duration of acute infectious diarrhea (viral gastroenteritis, including rotavirus diarrhea) in infants and children, as an adjunct to standard oral rehydration therapy.
• Prevention of antibiotic-associated diarrhea (AAD) in patients receiving antibiotic therapy, when started early in the course of antibiotics.

Adjunct / supportive uses

• General support of a balanced gut microbiota, for example after a course of antibiotics or during periods of dietary disruption.
• Adjunct supportive use alongside standard therapy for acute gastroenteritis in adults, though evidence is strongest in the pediatric population.

Uses with weaker or mixed evidence

• Reduction of Clostridioides difficile-associated diarrhea recurrence when used as an adjunct to standard antimicrobial treatment (evidence mixed; not a substitute for prescribed treatment).
• Prevention of atopic dermatitis in infants at high familial risk, when the mother is supplemented in late pregnancy and during breastfeeding, and/or the infant is supplemented directly (evidence inconsistent across studies).

Prolaxan is marketed as a dietary/food supplement (probiotic) in most markets, including Bangladesh, rather than as an approved prescription drug for a specific disease; it is intended to supplement, not replace, standard medical treatment.

Each dose unit (capsule, sachet, or chewable tablet, depending on the specific product) of Lactobacillus Rhamnosus GG contains a standardized quantity of viable Lactobacillus rhamnosus strain GG, expressed as colony-forming units (CFU), typically in the range of 1 to 20 billion (10⁹-2 × 10¹⁰) CFU per dose. The exact CFU count, excipients, and dosage form vary by brand and product strength; always check the specific product label.

Prolaxan is one of the most extensively studied probiotic bacterial strains in the world. It is a naturally occurring, non-pathogenic strain of Lactobacillus rhamnosus that survives passage through the acidic environment of the stomach and bile in the small intestine, allowing it to transiently colonize the gastrointestinal tract.

Prolaxan is used mainly to help prevent and shorten the duration of acute infectious diarrhea, and to reduce the risk of diarrhea associated with antibiotic use, by helping to restore and support a healthy balance of gut bacteria. It is not an antibiotic, does not directly kill pathogens, and is not a treatment for the underlying cause of an infection; rather, it works alongside the body's own defenses and, where relevant, alongside standard medical treatment such as oral rehydration or prescribed antibiotics.

Prolaxan belongs to the probiotic / live biotherapeutic product class of gut-health supplements, specifically the Lactobacillus-based probiotic subclass used for gastrointestinal and microbiota-support indications.

Lactobacillus Rhamnosus GG exerts its effects through several complementary, non-systemic mechanisms confined largely to the gastrointestinal lumen and mucosal surface:

• Competitive exclusion: adheres to intestinal epithelial cells and mucus, competing with pathogenic bacteria for binding sites and nutrients.
• Acid and antimicrobial substance production: ferments carbohydrates to produce lactic acid and other metabolites that lower local pH and inhibit the growth of several enteric pathogens.
• Mucosal barrier support: promotes mucin production and tight-junction integrity in the intestinal epithelium, helping to maintain gut barrier function.
• Immune modulation: stimulates secretory IgA production and modulates local cytokine responses, contributing to a balanced mucosal immune response.

Lactobacillus Rhamnosus GG is not absorbed systemically in clinically meaningful amounts; its actions are essentially local to the gastrointestinal tract, and it is naturally cleared from the gut within days to weeks after supplementation is stopped since it does not permanently colonize the colon in most individuals.

Prolaxan is taken by mouth. Capsules or sachets may be taken with or without food, though taking it with a meal or shortly after eating may help improve survival of the live organisms through the stomach. Sachet formulations can usually be mixed with a small amount of cool or lukewarm water, milk, or soft food (not hot food or drink, as heat can kill the live bacteria) and consumed immediately. If taken alongside an antibiotic, space the dose of Prolaxan at least 2 hours apart from the antibiotic dose to reduce the chance of the antibiotic killing the probiotic organisms.

No significant pharmacokinetic drug interactions have been established for Prolaxan, as it is not systemically absorbed. The main clinically relevant interaction is:

• Antibiotics: concurrent antibiotic therapy can reduce the viability of Prolaxan organisms in the gut. To minimize this effect, take Prolaxan at least 2 hours apart from antibiotic doses, though this may not completely prevent reduced efficacy.

Inform your physician or pharmacist of all medicines, supplements, and other probiotic products you are taking.

Prolaxan is generally very well tolerated. Reported effects include:

• Common: mild, self-limiting gastrointestinal symptoms on starting therapy, such as increased gas/flatulence, bloating, or mild abdominal discomfort, which usually resolve within a few days of continued use.
• Rare: in severely immunocompromised, critically ill, or hospitalized patients with central venous catheters or short bowel syndrome, rare cases of Lactobacillus bacteremia or, very rarely, fungemia related to probiotic use have been reported (see Precautions and Warnings).

Discontinue Prolaxan and seek medical advice if fever, signs of infection, or persistent worsening gastrointestinal symptoms develop.

Prolaxan has been used in pregnant and breastfeeding women in clinical studies without established evidence of harm, and is generally considered low risk. However, formal safety data remain limited compared with conventional pharmaceuticals. As a precaution, Prolaxan should be used during pregnancy and lactation only if clearly needed, and it is advisable to consult a physician before use in these situations, particularly at higher-than-typical doses.

While Prolaxan is well tolerated by most healthy individuals, caution is advised in the following situations, where the theoretical risk of probiotic-related bacteremia or infection is increased:

• Severe immunocompromise (e.g. advanced HIV/AIDS, chemotherapy-induced neutropenia, high-dose immunosuppressive therapy, organ transplant recipients).
• Presence of a central venous catheter.
• Critical illness or intensive-care-unit admission.
• Structural heart valve disease or a history of infective endocarditis.
• Short bowel syndrome or other conditions with significantly compromised intestinal mucosal integrity.

In these groups, use of Prolaxan should only be undertaken with specific medical advice, weighing potential benefit against the rare but reported risk of systemic infection. In all users, discontinue use and seek medical attention if fever or other signs of infection develop while taking Prolaxan. See Contraindications for hypersensitivity and Side Effects for further detail.

There is no well-defined toxic dose for Prolaxan, and it has a wide margin of safety in healthy individuals. Taking substantially more than the recommended dose may increase the likelihood of gastrointestinal symptoms such as bloating, gas, or loose stools. If a large accidental overdose is taken, especially in a young child, an immunocompromised person, or if symptoms of concern develop, seek immediate medical attention or contact a poison control center rather than attempting unsupervised home treatment.

Storage requirements for Prolaxan vary by product and formulation; some products require refrigeration (2-8°C) to preserve bacterial viability, while newer freeze-dried, shelf-stable formulations can be stored at room temperature (below 30°C). Always follow the specific storage instructions printed on the product label. In general, store away from direct light, heat, and moisture, and keep out of reach of children.

Renal/hepatic impairment: No specific dose adjustment of Prolaxan is established for renal or hepatic impairment, as it acts locally in the gut and is not systemically metabolized; standard dosing generally applies, but medical advice is recommended in significant organ impairment.

Elderly: No specific dose adjustment is required; standard adult dosing generally applies, though frail or hospitalized elderly patients with central lines should follow the caution noted in Precautions and Warnings.

Immunocompromised patients: see Precautions and Warnings.

Children and pregnancy/lactation: see Pediatric Uses and Pregnancy and Lactation.

For acute infectious diarrhea, Prolaxan is typically used for the duration of the diarrheal episode, generally 5-7 days, or until symptoms resolve. For prevention of antibiotic-associated diarrhea, it is typically used for the full duration of the antibiotic course. For general gut microbiota support, it may be used for shorter courses (e.g. 2-4 weeks) or longer term as advised by a physician or dietitian. If diarrhea persists beyond 7 days, worsens, or is accompanied by high fever, blood in stool, or signs of dehydration, medical attention should be sought rather than continuing self-treatment with Prolaxan alone.

Lactobacillus Rhamnosus GG belongs to the probiotic supplement / live biotherapeutic product drug class; specifically, it is a single-strain Lactobacillus-based probiotic used for gastrointestinal health.

Lactobacillus Rhamnosus GG works by transiently colonizing the intestinal mucosa, where it competes with pathogenic organisms for adhesion sites and nutrients, produces lactic acid and antimicrobial metabolites that lower luminal pH and inhibit pathogen growth, strengthens the intestinal mucosal barrier by promoting mucin secretion and tight-junction integrity, and modulates local mucosal immune responses including secretory IgA production. Together, these actions help shorten the duration of infectious diarrhea and reduce the disruption of gut microbiota caused by antibiotic therapy.

Prolaxan is commonly used in children, including infants, for the prevention and shortening of acute infectious diarrhea and for prevention of antibiotic-associated diarrhea, and has been studied extensively in pediatric populations. Dosing should follow product-specific, age-appropriate labeling (many products specify use from age 1 year and above; some formulations are labeled for use in younger infants under medical supervision). Safety and efficacy in neonates, premature infants, and severely immunocompromised or critically ill children have not been well established, and use of Prolaxan in these specific groups should only be undertaken with pediatrician guidance (see Precautions and Warnings).